Alectinib vs AQUA07

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline

Alectinib · Alecensa

Marketed by Roche and partners

Approved in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT02075840 · Phase 3 · completed

Participants were randomly assigned to alectinib or the active comparator crizotinib (152 versus 151), but the trial was open-label rather than double-blind. The primary progression-free survival endpoint was met, with alectinib showing a hazard ratio of 0.47 versus crizotinib (p<0.0001), but the lack of blinding limits the overall evidence strength.

Next expected readout: November 2026 · NCT04302025 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) as Determined by Investigator Using Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 (From the date of randomization to the date of the first documented disease progression or death, whichever occurred first (up to overall period of approximately 40 months)): Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019). (met)

Result source: NCT02838420

AQUA07

Developed by Chugai Pharma

Phase 1 in Non-Small Cell Lung Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2030 · NCT07617337 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlectinibAQUA07
PFS, median10.9 vs 1.4vs Premetrexed/Docetaxeln 79NCT02604342
5 other results
  • 25.7 vs 10.4 n 152 · Phase 3 · secondary NCT02075840
  • 7.1 vs 1.6 n 72 · Phase 3 · secondary NCT02604342
  • 8.2 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.4 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.9 n 138 · Phase 1/2 · secondary NCT01801111
—Not reported
OS, median81.1 vs 54.2vs Crizotinibn 152NCT02075840
3 other results
—Not reported
ORR82.9% vs 75.5%vs Crizotinibn 152NCT02075840
9 other results
—Not reported
Duration of response, median42.3 vs 11.1vs Crizotinibn 126NCT02075840
3 other results
  • 14.9 600 mg (Fed) · n 35 · Phase 1/2 · secondary NCT01871805
  • 13.3 600 mg (Fed) · n 46 · Phase 1/2 · secondary NCT01871805
  • 15.2 n 62 · Phase 1/2 · secondary NCT01801111
—Not reported

PFS, median

Alectinib
10.9 vs 1.4vs Premetrexed/Docetaxeln 79NCT02604342
5 other results
  • 25.7 vs 10.4 n 152 · Phase 3 · secondary NCT02075840
  • 7.1 vs 1.6 n 72 · Phase 3 · secondary NCT02604342
  • 8.2 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.4 600 mg (Fed) · n 87 · Phase 1/2 · secondary NCT01871805
  • 8.9 n 138 · Phase 1/2 · secondary NCT01801111
AQUA07
—Not reported

OS, median

Alectinib
81.1 vs 54.2vs Crizotinibn 152NCT02075840
3 other results
AQUA07
—Not reported

ORR

Alectinib
82.9% vs 75.5%vs Crizotinibn 152NCT02075840
9 other results
AQUA07
—Not reported

Duration of response, median

Alectinib
42.3 vs 11.1vs Crizotinibn 126NCT02075840
3 other results
  • 14.9 600 mg (Fed) · n 35 · Phase 1/2 · secondary NCT01871805
  • 13.3 600 mg (Fed) · n 46 · Phase 1/2 · secondary NCT01871805
  • 15.2 n 62 · Phase 1/2 · secondary NCT01801111
AQUA07
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AQUA07: no structured comparison results are available for Non-Small Cell Lung Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Alectinib: 4 of 4 rows · AQUA07: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlectinib
Dropout rate
n/a: no completion milestonea
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
n/a: no completion milestone
NCT02838420 · Phase 3 · monotherapy
54.4%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
n/a: no completion milestone
NCT01801111 · Phase 1/2
—600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
Discontinued due to AEs
0%a
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
—
NCT02838420 · Phase 3 · monotherapy
—
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
8.7%
NCT01801111 · Phase 1/2
—600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
Serious AEs
46.1%a
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
15.2%
NCT02838420 · Phase 3 · monotherapy
26%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
28.3%
NCT01801111 · Phase 1/2
24.1%600 mg (Fed)
NCT01871805 · Phase 1/2 · registry result, not featured evidence
Most frequent reported AEs
a
constipation 40.1%
anaemia 27.6%
blood bilirubin increased 24.3%
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
aspartate aminotransferase increased 52%
blood bilirubin increased 48.8%
blood creatine phosphokinase increased 44%
NCT02838420 · Phase 3 · monotherapy
constipation 20.8%
anaemia 15.6%
myalgia 14.3%
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
constipation 38.4%
fatigue 31.2%
oedema peripheral 30.4%
NCT01801111 · Phase 1/2
600 mg (Fed)
fatigue 41.4%
constipation 39.1%
headache 28.7%
NCT01871805 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alectinib

PFS NA vs 11.1 Crizotinib months
time to event · months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 4 more results
25.7 vs 10.4 Crizotinib months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
NA vs 11.1 Crizotinib months
NCT02838420 · Phase 3 · monotherapy
10.9 vs 1.4 Premetrexed/Docetaxel months
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
7.1 vs 1.6 Premetrexed/Docetaxel months
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
CNS Progression 11.8% (n=152) vs 45% (n=151) Crizotinib
responder rate · % of participants
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
10.5% (n=152) vs 35.8% (n=151) Crizotinib
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
ORR 82.9% (n=152) vs 75.5% (n=151) Crizotinib
responder rate · % of participants
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
48.1% (n=52) vs 0% (n=28) Premetrexed/Docetaxel
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
Duration of Response 42.3 vs 11.1 Crizotinib months
time to event · months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Overall Survival 81.1 vs 54.2 Crizotinib months
time to event · months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
show 1 more result
27.8 vs NA Premetrexed/Docetaxel months
NCT02604342 · Phase 3 · Non-Small Cell Lung Cancer · phase 3
CNS ORR 59.4% (n=152) vs 25.9% (n=151) Crizotinib
responder rate · % of participants
Measurable and non-measurable CNS lesions
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
CNS DOR 17.3 vs 5.5 Crizotinib months
absolute value · months
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration C30 Dyspnoea NA vs NA Crizotinib months
time to event · months
Dyspnea
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration LC13 Cough NA vs NA Crizotinib months
time to event · months
Coughing
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration Dyspnea 22.8 vs NA Crizotinib months
time to event · months
Dyspnea
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration LC13 Chest Pain NA vs NA Crizotinib months
time to event · months
Pain in chest
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3
Time to Deterioration Composite Symptoms 12.7 vs 21 Crizotinib months
time to event · months
Composite score (c, p in c, d)
NCT02075840 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3

+ 635 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alectinib's landscape · AQUA07's landscape